Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
André Fedier(University of Basel), Viola Heinzelmann‐Schwarz(Roche (Switzerland))
Cited by 9
Related Papers
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
|Cancer Cell|2021|140
Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells
|Fertility and Sterility|2010|46
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells
|International Journal of Oncology|2007|37
Low meprin α expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries
|Journal of Clinical Pathology|2006|25